Williams, G. P., Muskat, K., Frazier, A., Xu, Y., Mateus, J., Grifoni, A., da Silva Antunes, R., Weiskopf, D., Amara, A. W., Standaert, D. G., Goldman, J. G., Litvan, I., Alcalay, R. N., Sulzer, D., Lindestam Arlehamn, C. S., & Sette, A. (2023). Unaltered T cell responses to common antigens in individuals with Parkinson’s disease. Journal of the Neurological Sciences, 444, 120510. https://doi.org/10.1016/j.jns.2022.120510

McIntyre, L. M., Huertas, F., Morse, A. M., Kaletsky, R., Murphy, C. T., Kalia, V., Miller, G. W., Moskalenko, O., Conesa, A., & Mor, D. E. (2022). GAIT-GM integrative cross-omics analyses reveal cholinergic defects in a C. elegans model of Parkinson’s disease. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-07238-9

Wise, R. M., Wagener, A., Fietzek, U. M., Klopstock, T., Mosharov, E. V., Zucca, F. A., Sulzer, D., Zecca, L., & Burbulla, L. F. (2022). Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson’s disease and Neurodegeneration with Brain Iron Accumulation disorders. Neurobiology of Disease, 175, 105920. https://doi.org/10.1016/j.nbd.2022.105920

Cheng, F., Zheng, W., Liu, C., Barbuti, P. A., Yu-Taeger, L., Casadei, N., Huebener-Schmid, J., Admard, J., Boldt, K., Junger, K., Ueffing, M., Houlden, H., Sharma, M., Kruger, R., Grundmann-Hauser, K., Ott, T., & Riess, O. (2022). Intronic enhancers of the human SNCA gene predominantly regulate its expression in brain in vivo. Science Advances, 8(47). https://doi.org/10.1126/sciadv.abq6324

Hu, J., Waters, C. H., Spiegelman, D., Fon, E. A., Yu, E., Asayesh, F., Krohn, L., Saini, P., Alcalay, R. N., Hassin-Baer, S., Gan-Or, Z., Krainc, D., Zhang, B., Bustos, B. I., & Lubbe, S. J. (2022). Gene-based burden analysis of damaging private variants in PRKN, PARK7 and PINK1 in Parkinson’s disease cohorts of European descent. Neurobiology of Aging, 119, 136–138. https://doi.org/10.1016/j.neurobiolaging.2022.07.012

Shih, H.-J. S., Macpherson, C. E., King, M., Delaney, E., Gu, Y., Long, K., Reid, J., Fineman, J., Yu, G., Rieger, J., Satchidanand, A., Shah, H., Alcalay, R. N., & Quinn, L. (2022). Physical Activity Coaching via Telehealth for People With Parkinson Disease: A Cohort Study. Journal of Neurologic Physical Therapy, 46(4), 240–250. https://doi.org/10.1097/npt.0000000000000410

Louis, E. D., Iglesias-Hernandez, D., Hernandez, N. C., Flowers, X., Kuo, S.-H., Vonsattel, J. P. G., & Faust, P. L. (2022). Characterizing Lewy Pathology in 231 Essential Tremor Brains From the Essential Tremor Centralized Brain Repository. Journal of Neuropathology & Experimental Neurology, Publish Ahead of Print. https://doi.org/10.1093/jnen/nlac068

Heavener, K. S., & Bradshaw, E. M. (2022). The aging immune system in Alzheimer’s and Parkinson’s diseases. Seminars in Immunopathology, 44(5), 649–657. https://doi.org/10.1007/s00281-022-00944-6

Schiess, N., Cataldi, R., Okun, M. S., Fothergill-Misbah, N., Dorsey, E. R., Bloem, B. R., Barretto, M., Bhidayasiri, R., Brown, R., Chishimba, L., Chowdhary, N., Coslov, M., Cubo, E., Di Rocco, A., Dolhun, R., Dowrick, C., Fung, V. S. C., Gershanik, O. S., Gifford, L., … Dua, T. (2022). Six Action Steps to Address Global Disparities in Parkinson Disease. JAMA Neurology, 79(9), 929. https://doi.org/10.1001/jamaneurol.2022.1783

Sun, J., Ludvigsson, J. F., Ingre, C., Piehl, F., Wirdefeldt, K., Zagai, U., Ye, W., & Fang, F. (2022). Hospital-treated infections in early- and mid-life and risk of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis: A nationwide nested case-control study in Sweden. PLOS Medicine, 19(9), e1004092. https://doi.org/10.1371/journal.pmed.1004092

Saunders-Pullman, R., Ortega, R. A., Wang, C., Raymond, D., Elango, S., Leaver, K., Urval, N., Katsnelson, V., Gerber, R., Swan, M., Shanker, V., Alcalay, R. N., Mirelman, A., Brumm, M. C., Mejia-Santana, H., Coffey, C. S., Marek, K., Ozelius, L. J., Giladi, N., … Bressman, S. B. (2022). Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the LRRK2 G2019S Variant. Neurology, 99(8). https://doi.org/10.1212/wnl.0000000000200737

Crotty, G. F., Keavney, J. L., Alcalay, R. N., Marek, K., Marshall, G. A., Rosas, H. D., & Schwarzschild, M. A. (2022). Planning for Prevention of Parkinson Disease. Neurology, 99(7_Supplement_1), 1–9. https://doi.org/10.1212/wnl.0000000000200789

Bukhari, S. A., Nudelman, K. N. H., Rumbaugh, M., Richeson, P., Fox, E. J., Montine, K. S., Aldecoa, I., Garrido, A., Franz, J., Stadelmann, C., Vonsattel, J. P. G., Poston, K. L., Foroud, T. M., & Montine, T. J. (2022). Parkinson’s Progression Markers Initiative brain autopsy program. Parkinsonism & Related Disorders, 101, 62–65. https://doi.org/10.1016/j.parkreldis.2022.06.017

Chen, T. X., Lin, C.-Y. R., Aumann, M. A., Yan, Y., Amokrane, N., Desai, N. A., Kang, H., Claassen, D. O., & Kuo, S.-H. (2022). Impulsivity Trait Profiles in Patients With Cerebellar Ataxia and Parkinson Disease. Neurology, 99(2). https://doi.org/10.1212/wnl.0000000000200349

Wilkins, K. B., Petrucci, M. N., Kehnemouyi, Y., Velisar, A., Han, K., Orthlieb, G., Trager, M. H., O’Day, J. J., Aditham, S., & Bronte-Stewart, H. (2022). Quantitative Digitography Measures Motor Symptoms and Disease Progression in Parkinson’s Disease. Journal of Parkinson’s Disease, 12(6), 1979–1990. https://doi.org/10.3233/jpd-223264

Hallacli, E., Kayatekin, C., Nazeen, S., Wang, X. H., Sheinkopf, Z., Sathyakumar, S., Sarkar, S., Jiang, X., Dong, X., Di Maio, R., Wang, W., Keeney, M. T., Felsky, D., Sandoe, J., Vahdatshoar, A., Udeshi, N. D., Mani, D. R., Carr, S. A., Lindquist, S., … Khurana, V. (2022). The Parkinson’s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability. Cell, 185(12), 2035-2056.e33. https://doi.org/10.1016/j.cell.2022.05.008

Xu, Y., Feeney, M. P., Surface, M., Novak, D., Troche, M. S., Beck, J. C., & Alcalay, R. N. (2022). Attitudes Toward Telehealth Services Among People Living With Parkinson’s Disease: A Survey Study. Movement Disorders, 37(6), 1289–1294. Portico. https://doi.org/10.1002/mds.28990

Hobson, B. D., & Sulzer, D. (2022). Neuronal Presentation of Antigen and Its Possible Role in Parkinson’s Disease. Journal of Parkinson’s Disease, 12(s1), S137–S147. https://doi.org/10.3233/jpd-223153

Wise, A. H., & Alcalay, R. N. (2022). Genetics of cognitive dysfunction in Parkinson’s disease. Cognition in Parkinson’s Disease, 195–226. https://doi.org/10.1016/bs.pbr.2022.01.015

Pal, G., Mangone, G., Hill, E. J., Ouyang, B., Liu, Y., Lythe, V., Ehrlich, D., Saunders‐Pullman, R., Shanker, V., Bressman, S., Alcalay, R. N., Garcia, P., Marder, K. S., Aasly, J., Mouradian, M. M., Link, S., Rosenbaum, M., Anderson, S., Bernard, B., … Goetz, C. G. (2022). Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Annals of Neurology, 91(3), 424–435. Portico. https://doi.org/10.1002/ana.26302

Griffey, C. J., & Yamamoto, A. (2022). Living in α-syn: Tackling aggregates in Parkinson’s disease. Neuron, 110(3), 351–352. https://doi.org/10.1016/j.neuron.2022.01.016

Garretti, F., Monahan, C., Sette, A., Agalliu, D., & Sulzer, D. (2022). T cells, α-synuclein and Parkinson disease. Neuroplasticity - From Bench to Bedside, 439–455. https://doi.org/10.1016/b978-0-12-819410-2.00023-0

Peterschmitt, M. J., Saiki, H., Hatano, T., Gasser, T., Isaacson, S. H., Gaemers, S. J. M., Minini, P., Saubadu, S., Sharma, J., Walbillic, S., Alcalay, R. N., Cutter, G., Hattori, N., Höglinger, G. U., Marek, K., Schapira, A. H. V., Scherzer, C. R., Simuni, T., … Fischer, T. Z. (2022). Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. Journal of Parkinson’s Disease, 12(2), 557–570. https://doi.org/10.3233/jpd-212714